Details for Patent: 7,959,945

Which drugs does patent 7,959,945 protect, and when does it expire?

Patent 7,959,945 protects TRACLEER and is included in one NDA.

This patent has twenty-eight patent family members in twenty-three countries.

Summary for Patent: 7,959,945

Title:	Dispersible bosentan tablet
Abstract:	The invention relates to dispersible tablets comprising the compound 4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-(pyrimidin-2- -yl)-pyrimidin-4-yl]-benzenesulfonamide.
Inventor(s):	Holman; Lovelace (Arlesheim, CH), Trenktrog; Timm (Binningen, CH)
Assignee:	Actelion Pharmaceuticals Ltd. (Allschwil, CH)
Application Number:	11/914,652
Patent Claim Types: see list of patent claims	Compound; Dosage form;

Drugs Protected by US Patent 7,959,945

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Actelion	TRACLEER	bosentan	TABLET, FOR SUSPENSION;ORAL	209279-001	Sep 5, 2017		RX	Yes	Yes			Y

Foreign Priority and PCT Information for Patent: 7,959,945

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	PCT/EP2005/005367	May 17, 2005

PCT Information
PCT Filed	May 15, 2006	PCT Application Number:	PCT/IB2006/051519
PCT Publication Date:	November 23, 2006	PCT Publication Number:	WO2006/123285

International Family Members for US Patent 7,959,945

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	E451914
Australia	2006248593
Brazil	PI0610187
Canada	2607098
China	101175484